Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
STSS 
Sharps Technology Inc (STSS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: STSS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.78% | Avg. Invested days 6 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.40M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 1 | Beta 2.14 | 52 Weeks Range 3.36 - 2145.00 | Updated Date 08/29/2025 |
52 Weeks Range 3.36 - 2145.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1196.84 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.94 | Actual 3.58 |
Profitability
Profit Margin - | Operating Margin (TTM) -1349.84% |
Management Effectiveness
Return on Assets (TTM) -50.38% | Return on Equity (TTM) -6.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19301701 | Price to Sales(TTM) 73.64 |
Enterprise Value 19301701 | Price to Sales(TTM) 73.64 | ||
Enterprise Value to Revenue 86.66 | Enterprise Value to EBITDA -2.19 | Shares Outstanding 1023210 | Shares Floating 1021996 |
Shares Outstanding 1023210 | Shares Floating 1021996 | ||
Percent Insiders 74.39 | Percent Institutions 1.81 |
Upturn AI SWOT
Sharps Technology Inc
Company Overview
History and Background
Sharps Technology, Inc., founded in 2017, focuses on developing and manufacturing innovative safety syringe products. The company aims to reduce needlestick injuries and improve drug delivery.
Core Business Areas
- Sharps Provensa: This segment focuses on the manufacturing and distribution of the Sharps Provensa line of auto-retractable safety syringes. These syringes are designed to prevent needlestick injuries and ensure single use.
- Contract Manufacturing: This segment involves providing contract manufacturing services for other medical device companies, leveraging Sharps' manufacturing capabilities and expertise.
Leadership and Structure
Robert Hayes serves as the CEO. The company has a board of directors overseeing strategic direction and corporate governance. The organization is structured with functional departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Sharps Provensa Safety Syringe: The Sharps Provensa syringe is an auto-retractable safety syringe designed to prevent needlestick injuries. Market share data is limited as of late 2023, but they are targeting a portion of the global safety syringe market, estimated to be in the billions. Competitors include Becton Dickinson (BDX) and Smiths Medical.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by technological advancements, aging populations, and increasing healthcare spending. The safety syringe market is growing due to heightened awareness of needlestick injuries and stringent regulatory requirements.
Positioning
Sharps Technology is positioned as an innovator in safety syringe technology, aiming to capture market share by offering superior safety features and ease of use. Their competitive advantage lies in their proprietary auto-retractable design.
Total Addressable Market (TAM)
The global safety syringe market is estimated at several billion USD annually. Sharps Technology is targeting a significant portion of this TAM by focusing on specific market segments such as hospitals, clinics, and vaccination programs.
Upturn SWOT Analysis
Strengths
- Innovative product design (auto-retractable safety syringe)
- Strong focus on safety and prevention of needlestick injuries
- Potential for cost-effective manufacturing
- Focus on a high-growth market segment
Weaknesses
- Limited market share compared to established competitors
- Reliance on single product line (Provensa)
- Potential dependence on third-party manufacturers or suppliers
- Relatively small company size compared to industry giants
Opportunities
- Expanding into new geographic markets
- Developing new safety syringe products for different applications
- Partnering with pharmaceutical companies for drug delivery systems
- Acquiring smaller competitors or complementary technologies
Threats
- Competition from established medical device companies
- Price pressure from generic safety syringes
- Regulatory changes affecting medical device approvals
- Potential for product liability claims
Competitors and Market Share
Key Competitors
- BDX
- SMIT
- NIPD
Competitive Landscape
Sharps Technology faces intense competition from established players with greater resources and market presence. To succeed, Sharps must continue to innovate, build strong customer relationships, and execute its growth strategy effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires access to the company's financial reports and stock price history, which are not fully available for this response.
Future Projections: Future growth projections are not available. Analysts' estimates vary based on market conditions and company performance.
Recent Initiatives: Recent initiatives include scaling up manufacturing capacity, expanding sales and marketing efforts, and pursuing regulatory approvals for their safety syringe products in new markets.
Summary
Sharps Technology is a small company in a very competitive market with a product with high market potential. They need to scale up production and sales to take advantage of their proprietary product. Their financial stability will be very important and needs to be watched. Successfully navigating the regulatory landscape is vital for growth. They should consider strategic partnerships for expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Please consult with a financial advisor before making any investment decisions. Market share data may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 55 | Website https://sharpstechnology.com |
Full time employees 55 | Website https://sharpstechnology.com | ||
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. The company was incorporated in 2017 and is based in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.